How to Start a Peptide Company: The Order the Decisions Have to Go In

The order of the decisions matters more than any single decision

Most guides to starting a peptide company present a checklist: form an entity, find a supplier, build a store, get processing, launch. Everything on that list is real. The list is still wrong, because it is unordered, and in this category the order is what determines whether the later steps are available to you.

Two decisions made early foreclose options later. One is what you sell and how you describe it, which determines the regulatory regime the whole business operates in. The other is whether you take title to inventory, which determines your licensing obligations and your working capital at the same time. Both are cheap to decide and expensive to reverse.

This article sequences the decisions by what each one forecloses.

Decision one: what the product legally is

This is first because everything else inherits from it, and because the answer is not a property of the molecule.

Under 21 CFR 201.128, what a product is intended for is determined by the objective intent of the seller, read from labeling, advertising, and the circumstances of the sale. Two companies shipping identical material can occupy different regulatory positions because they describe it differently.

The practical consequence is that your positioning is not a marketing decision made after launch. It is the decision that determines which body of law the business sits under, which in turn determines whether wholesale distribution licensing attaches, whether the catalog is sellable through mainstream payment processing, and what a warning letter would say if one arrived.

Deciding this first means writing the boundaries of what the business will and will not claim before writing a single product page. Deciding it last means discovering the boundary by crossing it.

There is a practical way to make this decision concrete rather than abstract. Write the sentences you will not publish, as sentences, before you write the ones you will. A boundary expressed as a principle survives contact with a copywriter for about one draft. A boundary expressed as a list of specific forbidden constructions survives, because it can be checked mechanically by anyone, including someone who joins the business later and was not in the room when the positioning was decided.

That list is also the artifact a payment processor's review is effectively testing when it looks at your site, and it is the artifact that makes the difference between a compliance posture and a compliance intention.

Decision two: whether you take title

This is second because it determines both your licensing exposure and your capital requirement, and because it is a contract term you set rather than a condition you inherit.

Under 21 USC 353(e), wholesale distribution of a drug subject to subsection (b)(1) requires the distributor to be licensed by the state from which the drug is distributed, or by the Secretary where the state has not established a licensure requirement, and additionally by the destination state where that state requires licensure of persons distributing into it.

The statute handles logistics differently, and conditionally. A third-party logistics provider licensed under section 360eee-3(a) "is not required to obtain a license as a wholesale distributor", with the exclusion available "provided that such third-party logistics provider does not take ownership of the drug". The same ownership condition governs common carriers.

Title is therefore the hinge, and it is decided in a contract before any inventory moves. Take title and you own inventory risk, storage conditions, and a possible licensing obligation. Do not take title and you own less of all three, and less margin with it.

Decision three: supplier, chosen against documentation rather than price

Third, because the first two decisions constrain what a supplier must be able to provide, and choosing a supplier before knowing that is how operators end up locked into a relationship that cannot support the model.

The question is not who is cheapest. It is who can produce batch-level documentation on a recurring basis, because per-lot verification is a running control rather than a one-time qualification. A supplier who provides a document at onboarding and nothing afterwards has sold a relationship, not a control.

Minimum order quantity belongs to this decision too, because it converts catalog strategy into a working capital number. Breadth of catalog multiplied by minimum order quantity is the capital tied up before the first sale.

That arithmetic tends to argue for a narrower launch than most operators plan, and the argument is stronger than it first appears. A narrow catalog does not only cost less to stock. It costs less to verify per lot, less to describe accurately, and less to review when a policy or a classification changes, because every one of those recurring costs is charged per product rather than per business. Breadth is therefore not a single decision about assortment. It is a multiplier applied to every ongoing obligation the business has, and it is far easier to add a product later than to unwind an inventory position in one that did not sell.

Decision four: the business registrations, which are not licenses

Fourth, because they are necessary and because getting them early creates a false sense that the regulatory question has been handled.

Entity formation is a state corporate filing. The Internal Revenue Service business structures guidance covers the choice between sole proprietorship, partnership, corporation, and limited liability company. Sales tax registration and a resale certificate are revenue-department matters in each state where you have nexus.

Neither confers authority to distribute anything. An operator holding a limited liability company, an employer identification number, and a resale certificate has completed the formation layer and has not touched the question in decision one or decision two. The formation layer is genuinely necessary and it is also the layer that produces the most visible early progress, which is exactly why it gets mistaken for readiness.

Establishment registration and listing is a separate Food and Drug Administration process described in the agency's registration and listing guidance, and it applies to establishments that manufacture, prepare, propagate, compound, or process drugs rather than to those that distribute them.

Decision five: payment processing, applied for last and prepared for first

Fifth in sequence and first in preparation, which is the part that catches people.

Processors publish what they will not accept. Stripe's restricted businesses list names nutraceuticals and pseudo-pharmaceuticals among restricted categories, identifying pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims, and separately names incorrectly labeled research chemicals. PayPal's acceptable use policy prohibits transactions involving certain categories of regulated substance.

Neither list bans the substances. Both attach to claims and labeling, which means the underwriting review is a review of decision one. Approval at signup is an automated check that the application is well formed; the substantive review happens later, with the live site in front of it.

Applying before the site is right means reapplying with a record. Preparing the site first and applying once is the same work in a better order.

What the sequence produces

Run in this order, each decision constrains the next and none of them has to be undone. The positioning decision tells you what the supplier must document. The title decision tells you what licensing to investigate and how much capital the model needs. The supplier decision tells you the catalog you can actually support. The registrations follow. The processing application is made against a site that already reflects all of it.

Run in the usual order, the store gets built first, the processing application goes in against whatever the store happens to say, and the positioning question gets answered by a decline notice or a review.

The difference between the two orders is not effort, and that is the part worth sitting with. Both sequences involve the same five decisions and roughly the same number of hours. What changes is how many of those decisions have to be made twice, because a decision made without its constraint is a decision that gets revisited once the constraint appears.

Reversing a positioning decision means rewriting every product page. Reversing a title decision means renegotiating a supplier agreement and often re-capitalizing the business. Reversing a supplier decision means absorbing whatever inventory the minimum order quantity forced you to buy. Reversing a processing decision means reapplying with a declined application already on record. None of those is fatal on its own, and the cost of all four together is what makes the difference between a business that launches once and one that keeps restarting.

The sequence is not a best practice, then. It is an ordering that makes each decision cheap by making sure the information it needs already exists when it is taken.

The position, stated plainly

Our view, stated as judgment rather than as a measured finding: most peptide companies that fail do not fail at execution. They fail at sequencing, and sequencing is free.

That claim is worth being precise about, because it is easy to hear as a platitude. We are not saying planning beats doing. We are saying something narrower and more testable. Four of the five decisions above are expensive to reverse, all four are decidable before any money moves, and the usual order forces at least two of them to be made twice. The cost of the wrong order is not a mistake you can work harder to escape, because the work has already been done and has to be undone.

Compare it to the parts of this business that genuinely are hard. Sourcing well is hard. Writing a product page that is accurate and still persuasive is hard. Building demand in a category where the obvious advertising channels are closed is very hard. Sequencing is not hard. It requires an afternoon and a willingness to sit with an unglamorous question before touching the enjoyable ones.

That is the whole argument, and its strength is also its irritation: the cheapest available advantage in this category is the one that feels least like progress.

It is also, for the same reason, the most reliably available one. Advantages that cost money get competed away by whoever has more money. Advantages that require talent get competed away by whoever has more talent. An advantage that costs an afternoon and feels boring survives, because the thing protecting it is not scarcity of resources but a near-universal preference for starting with the fun part. That preference is not going to change, which makes this a durable edge for anyone willing to spend one afternoon differently.

The strongest argument against this

The strongest objection comes from people who have actually built things, which is why it deserves more than a nod. It runs like this. You cannot plan a business into existence. Real information arrives when you ship, customers tell you things no amount of upfront analysis would have surfaced, and an operator who tries to settle every decision before launching mostly discovers they settled them wrongly with less information than they would have had later. Bias to action beats bias to sequence.

We think that is right, and it is right about a category of decision this article is not describing. Pricing, positioning, assortment, channel, and copy all improve with contact and should be shipped early and revised often. Learning by doing is the correct method there, and an operator who waits to perfect them on paper is wasting the only real feedback available.

The distinction that matters is reversibility. Ship the reversible decisions fast, and we would push harder on that than most. Settle the irreversible ones first, because the feedback you get from shipping them is not information you can act on. It is a bill. The four decisions above are in the second group, and that is the only reason we argue for sequencing them at all.

What this does not cover

This is a sequencing argument for the United States federal layer and its state interface. It is not legal, tax, or financial advice, and it does not resolve any specific business.

It does not enumerate state wholesale distribution programs, which differ in scope, fee, bonding, and inspection. It does not cover controlled substances, which sit under a separate Drug Enforcement Administration regime. It does not cover non-United States jurisdictions. It contains no cost figures, because supplier terms and catalog decisions drive them too strongly for a published number to transfer. General, non-category-specific cost methodology is in the Small Business Administration startup cost guidance.

Frequently asked questions

What is the first step in starting a peptide company?

Deciding what the product legally is, because intended use under 21 CFR 201.128 is read from labeling, advertising, and the circumstances of the sale, and every later decision inherits from it.

Do I need to form an LLC first?

Entity formation is necessary and is not the constraining decision. It is a state corporate filing that confers no authority to distribute, so it can be done at any point without foreclosing anything.

Can I get payment processing before the site is finished?

You can apply, and approval at signup is largely an automated check that the application is well formed rather than a decision about your business. The substantive underwriting review comes later and looks at the live site. Applying early against an unfinished site therefore risks a decline recorded against you, and reapplying with a declined application already on file is a materially harder conversation than applying once against a site that is ready.

Should I hold inventory or use a fulfillment partner?

That is the title question, and it sets both the licensing analysis and the working capital requirement. The statute's third-party logistics lane is conditioned on the provider not taking ownership of the drug.

How many products should I launch with?

Catalog breadth multiplied by minimum order quantity is capital committed before the first sale, and each product carries a recurring per-lot verification cost. Breadth is a capital decision rather than an assortment decision.

Where this fits

The licensing layer is covered in do you need a license to sell peptides, the operating models are separated in how to become a peptide distributor, the cost structure is in is a peptide business profitable, and the positioning decision is covered in research use only, what it actually means.

All compounds referenced anywhere on this site are supplied strictly for laboratory research purposes only. Nothing here is for human consumption, and nothing here is intended to diagnose, treat, cure, or prevent any disease.